TITLE

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkins lymphoma: CALGB 59804

AUTHOR(S)
NL Bartlett; D Niedzwiecki; JL Johnson; JW Friedberg; KB Johnson; K van Besien; AD Zelenetz; BD Cheson; GP Canellos; For the Cancer Leukemia Group B
PUB. DATE
June 2007
SOURCE
Annals of Oncology;Jun2007, Vol. 18 Issue 6, p1071
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkins lymphoma (HL). Patients and methods: A total of 91 patients participated. GVD was administered on days 1 and 8 every 21 days at doses of G 1000 mg/m2, V 20 mg/m2, and D 15 mg/m2 for transplant-naive patients, and G 800 mg/m2, V 15 mg/m2, and D 10 mg/m2 for post-transplant patients. Results: The dose-limiting toxicity was mucositis for the transplant-naive patients and febrile neutropenia for post-transplant patients. The overall response rate (RR) for all patients was 70% [95% confidence interval (CI) 59.8, 79.7], with 19% complete remissions. The 4-year event-free and overall survival rates in transplant-naive patients treated with GVD followed by autologous transplant were 52% (95% CI 0.34, 0.68) and 70% (95% CI 0.49, 0.84), and in the patients in whom prior transplant failed, these were 10% (95% CI 0.03, 0.22) and 34% (95% CI 0.17, 0.52), respectively. Conclusions: GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens. High RRs in patients in whom prior transplant failed confirms this regimens activity even in heavily pretreated patients.
ACCESSION #
25588570

 

Related Articles

  • Die Nachsorge beim Hodgkin-Lymphom. Renner, Christoph // Praxis (16618157);12/25/2011, Vol. 100 Issue 25, p1515 

    No abstract available.

  • Hodgkin Lymphoma.  // Current Medical Literature: Leukemia & Lymphoma;2008, Vol. 16 Issue 2, p52 

    The article presents the results of two studies related to Hodgkin lymphoma treatment. The first study examined the effect of combining gemcitabine and rituximab for treating patients with recurrent or refractory Hodgkin lymphoma. The other study compared the effectiveness of reduced-intensity...

  • Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant. Iqbal, Nida; Kumar, Lalit; Iqbal, Naveed // ISRN Otolaryngology;2014, p1 

    Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10-30% of cases and 5-10% patients are nonresponsive to initial chemotherapy. The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% of patients...

  • Doxorubicin liposomal.  // Reactions Weekly;2/4/2012, Issue 1387, p17 

    The article describes the case of a 37-year-old man developed palmoplantar erythrodysaesthesia (PPE) while receiving pegylated (PLD) and non-pegylated doxorubicin (NPLD) liposomal for Hodgkin's disease.

  • BEACOPP regimen associated with high rate of OS in high-risk Hodgkin's lymphoma.  // Hem/Onc Today;4/25/2011, Vol. 12 Issue 8, p3 

    The article reports on results of a study which showed the effectiveness of high-dose BEACOPP chemotherapy on children and adolescents who have high-risk Hodgkin's lymphoma.

  • Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody-Drug Conjugates: Focus on Brentuximab Vedotin. Mei, Matthew; Thomas, Sandra; Chen, Robert // BioDrugs;Jun2014, Vol. 28 Issue 3, p245 

    Brentuximab vedotin (Adcetris, Seattle Genetics) is an antibody-drug conjugate (ADC) that joins an anti-CD 30 monoclonal antibody with the anti-tubulin agent monomethyl auristatin E via a dipeptide linker. It has demonstrated significant activity in CD 30-positive lymphomas and is currently...

  • Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Gertz, M A; Wolf, R C; Micallef, I N M; Gastineau, D A // Bone Marrow Transplantation;Sep2010, Vol. 45 Issue 9, p1396 

    High-dose chemotherapy in conjunction with auto-SCT is the preferred treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma and newly diagnosed multiple myeloma. Failure to achieve optimal stem cell mobilization results in multiple subsequent attempts, which consumes large amounts of...

  • Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report. Moore, Melvin R.; Bull, Joan M.; Jones, Stephen E.; Rosenberg, Saul A.; Kaplan, Henry S.; Moore, M R; Bull, J M; Jones, S E; Rosenberg, S A; Kaplan, H S // Annals of Internal Medicine;Jul72, Vol. 77 Issue 1, p1 

    Focuses on a study which examined the efficacy of radiation therapy and chemotherapy in treating Hodgkin's disease. Characteristics of patients; Toxicities that occurred during chemotherapy; Survival of patients.

  • Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease. Devita, Vincent T.; Serpick, Arthur A.; Carbone, Paul P. // Annals of Internal Medicine;Dec70, Vol. 73 Issue 6, p881 

    Examines a case involving patients with advanced primarily untreated Hodgkin's disease who were treated with a combination of vinscristine sulfate, nitrogen mustard, procarbazine hydrochloride and prednisone. Information on Hodgkin's disease; Clinical features and response of patients to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics